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The Membrane-Anchored MMP Inhibitor RECK
Is a Key Regulator of Extracellular Matrix
Integrity and Angiogenesis
by MMP-2 null mutation. Also, vascular sprouting is
dramatically suppressed in tumors derived from RECK-
expressing fibrosarcoma cells grown in nude mice.
These results support a role for RECK in the regulation
of MMP-2 in vivo and implicate RECK downregulation
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volved in carcinogenesis, since correlation between
Cell
790
their activity and the malignancy of tumors has been
documented in a number of studies (Davies et al., 1993;
Yamamoto et al., 1996; Kahari and Saarialho-Kere, 1999;
Coussens et al., 2000). Moreover, in preclinical studies,
synthetic MMP inhibitors have been found to inhibit tu-
mor growth and metastasis (Hidalgo and Eckhardt,
2001).
The RECK gene was isolated by an expression cloning
strategy designed to isolate human cDNAs inducing flat
reversion in a v-Ki-ras-transformed NIH3T3 cell line
(Noda et al., 1989; Kitayama et al., 1989; Takahashi et
al., 1996). The RECK-encoded glycoprotein (molecular
weight 110,000) contains serine protease inhibitor-like
domains and is associated with the cell membrane
through a carboxy-terminal glycosylphosphatidylinosi-
tol (GPI)-modification (Takahashi et al., 1998). While the
RECK gene is widely expressed in various human or-
gans, its expression is low or undetectable in many
tumor-derived cell lines; also, RECK expression can be
downregulated by several oncogenes, including ras (Ta-
kahashi et al., 1998; Sasahara et al., 1999). When RECK
gene expression was artificially restored in several tu-
mor-derived cell lines, the amount of extracellular pro-
MMP-9 produced by these cells was reduced, and their
invasive and metastatic potentials were suppressed (Ta-
kahashi et al., 1998), suggesting a role for RECK in the
regulation of MMP-9 and tumor malignancy.
In the present study, we further evaluated the bio-
chemical activities of RECK and explored its biological
functions in vivo through gene targeting experiments as
well as tumor transplantation experiments in mice. The
results indicate that RECK negatively regulates two
other MMPs, MMP-2 and MT1-MMP, and document the
importance of RECK in the regulation of ECM remodel-
ing and blood vessel formation.
Results
Downregulation of Active MMP-2 by RECK
Since RECK was originally identified as a membrane-
associated negative regulator of MMP-9 (Takahashi et
al., 1998), we used the human fibrosarcoma-derived cell
line HT1080, which expresses both MMP-2 and MMP-9
but does not express RECK, to determine if RECK might
also regulate MMP-2. When conditioned medium from
HT1080 cells transfected with a control vector was ana-
extracted from HT1080 transfectants were analyzed by RNA blot
hybridization or immunoblot assay, respectively.
(D) Effects of RECK on MT1-MMP activity in vitro. Left panel: MT1-F
protein expressed in E. coli and partially purified was analyzed by
SDS-PAGE (stained with Coomassie blue). The identity of the top
band is unknown. Right panel: the bead-bound MT1-F was mixed
with 4 pmol BSA (bar 2), 2 pmol (bars 3, 6), or 4 pmol (bar 4) hRECKC
in the absence (bars 1–4) or presence (bars 5 and 6) of 0.25 pmol
Figure 1. RECK Regulates Three MMPs TIMP-2, and proteolytic activity was measured using a fluorescent
(A) Effects of RECK on the production of gelatinolytic enzymes by MMP substrate. Error bars represent SE from three independent
HT1080 cells. Either fresh medium (lane 1), conditioned medium measurements.
prepared from a pool of vector-transfected HT1080 cells (lane 2), (E) Effects of RECK on APMA-activated MMP-2. Pro-MMP-2 was
or conditioned media from RECK-transfected HT1080 cells (lane 3) activated with APMA and its proteolytic activity measured using
was analyzed by gelatin zymography. The molecular species corre- increasing concentrations (1–10 M) of fluorescent MMP substrate
sponding to each band is indicated on the right. in the absence (filled circle) or presence (open circle) of hRECKC
(B and C) Effects of RECK on the expression of MT1-MMP, MMP-2, (3.5 pmol). Data are presented as a double reciprocal Lineweaver-
and TIMP-2 in HT1080 cells. The mRNA (B) or total proteins (C) Burk plot. The Ki value obtained from these data is 80 nM.
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Figure 2. Generation of RECK-Deficient Mice
(A) Targeting strategy.
(B) Proportion of surviving RECK/ embryos at indicated stages. n, number of embryos observed.
(C) RNA blot analysis for RECK expression in cells from heterozygous (/) or homozygous (/) mutant embryos (left panel). An ethidium-
stained membrane is also shown (right panel).
(D) Immunoblot analysis for RECK protein in whole embryo lysates.
(E–L) Morphology of the wild-type (left panels) and RECK/ (right panels) E10.5 embryos.
(E) Unfixed embryos.
(F) Whole embryo sections stained with anti-RECK antibodies.
(G and H) Disarray of vascular endothelial cells in the RECK/ embryo. Relatively large (G) and small (H) blood vessels in sections stained
with anti-CD31 antibodies are shown.
(I–K) Visualization of the vascular network in the embryo proper by whole-mount immunohistochemistry. (I) Embryos stained with anti-CD31
antibodies. Higher magnification of the head regions (J) and the trunk regions (K) are also shown.
(L) Vascular network in yolk sacs stained with anti-Flk-1 antibodies.
Scale bar: 0.5 mm in E and J; 1 mm in F; 50 m in G–I; 0.2 mm in K–M.
lyzed by gelatin zymography, we could detect four major is formed on the cell surface, and the pro-MMP-2 is
cleaved at a specific site (Asn37-Leu38 in the human pro-bands: the 92 kilodalton (kDa) band corresponding to
the molecular weight (MW) of pro-MMP-9, and a triplet tein) by a second MT1-MMP molecule to yield the inter-
mediate form of MMP-2. Second, the removal of theof bands around 70 kDa corresponding (from top to
bottom) to the MW of the pro-, intermediate, and active residual prodomain is achieved through intermolecular,
autoproteolytic cleavage, and is accompanied by re-forms of MMP-2 (Figure 1A, lane 2). When RECK was
expressed in these cells, the amount of secreted pro- lease of active MMP-2 from the membrane. Thus, a
simple mechanism which would explain the observedMMP-9 and active MMP-2 were significantly reduced
(Figure 1A, lane 3). A less drastic, but reproducible, re- downregulation of active MMP-2 would be the upregula-
tion of TIMP-2, since TIMP-2 is known to inhibit MT1-duction in the amount of the intermediate form of MMP-2
was also noted. Immunoblot assays, however, indicated MMP as well as active MMP-2 in vitro. RECK does not,
however, alter the level of TIMP-2 mRNA (Figure 1B).that RECK did not affect the total amount of MMP-2
protein associated with the cells (Figure 1C). Interest- Downregulation of MT1-MMP expression could also ex-
plain our finding; however, the level of MT1-MMP ex-ingly, we previously showed that the amount of MMP-9
mRNA expressed by HT1080 cells is not affected by pression was not reduced by RECK (Figures 1B and 1C).
We therefore tested the possibility of direct enzymaticRECK expression (Takahashi et al., 1998). Thus, RECK
regulates MMP-2 and MMP-9 posttranscriptionally. inhibition of MT1-MMP activity using purified recombi-
nant proteins. In this assay, we employed a soluble MT1-
MMP protein (MT1-F; Kinoshita et al., 1998) lacking theInhibition of MT1-MMP by RECK
Processing of pro-MMP-2 takes place by two consecu- NH2-terminal prodomain and containing the FLAG-epi-
tope in place of the COOH-terminal transmembrane do-tive proteolytic cleavages which occur preferentially at
the plasma membrane (reviewed in Ellerbroek and main (Figure 1D, left panel). The RECK protein employed
in this assay (hRECKC) was also a soluble form whichStack, 1999). First, a membrane-anchored ternary com-
plex consisting of MT1-MMP, TIMP-2, and pro-MMP-2 lacks the COOH-terminal GPI-anchoring domain but re-
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tains invasion-suppressing activity (Takahashi et al., networks (as revealed by whole-mount immunostaining
for endothelial markers) are formed in the mutant em-1998). Consistent with previous observations, the activ-
ity of MT1-F, as assayed using a fluorescent MMP sub- bryo as well as in the yolk sac (Figures 2I–2L, right
panels), their morphology resembles primitive vascularstrate (Mca-P-L-G-L-Dpa-A-R; Knight et al., 1992), was
sensitive to TIMP-2 (Figure 1D, right panel, bar 5). In this plexuses, suggesting defects in blood vessel matura-
tion, rather than vasculogenesis.assay, the hRECKC protein inhibited MT1-F activity in
a dose-dependent manner (Figure 1D, bars 3 and 4),
and the effects of hRECKC and TIMP-2 were additive Effects of RECK Deficiency on MMPs
(Figure 1D, bar 6). These results suggest that RECK can and ECM Proteins
directly inhibit MT1-MMP. Consistent with the effects of RECK on pro-MMP-2 pro-
cessing in HT1080 cells described above (Figure 1A),
conditioned media prepared from RECK/ embryonicInhibition of MMP-2 by RECK
The data in Figure 1A suggest that the second step of cells contained elevated levels of active MMP-2 com-
pared to those from RECK/ and / littermates (Figurepro-MMP-2 processing (i.e. conversion of the intermedi-
ate form to the active form by autoproteolysis) is dramat- 3A). As expected, pro-MMP-9—which is not expressed
until E11 (Canete-Soler et al., 1995)—was not detected.ically inhibited by RECK expression. We therefore exam-
ined the effects of purified RECK protein (hRECKC) on Also, when fibroblastic cell lines (MEF) established from
RECK/ embryos were transfected with a RECK-expres-the activity of MMP-2 in vitro. Purified recombinant pro-
MMP-2 was activated by treatment with a sulfhydryl-reac- sion vector, their conditioned media contained reduced
levels of active MMP-2 (Figure 3B). Thus, the absence oftive compound, aminophenylmercuric acetate (APMA),
and the resulting proteolytic activity against Mca-P-L- RECK expression likely results in disinhibition of MMP-2,
and presumably MT1-MMP, as predicted by the bio-G-L-Dpa-A-R was measured in the absence or presence
of hRECKC. A Lineweaver-Burk plot of the data shows chemical data, leading to excessive degradation of the
ECM.that hRECKC competitively inhibits MMP-2 with a cal-
culated Ki value of 80 nM (Figure 1E), which is similar This hypothesis was examined by several approaches
comparing RECK/ and RECK/ littermates. First, theto the Ki value for this protein against MMP-9 (Takahashi
et al., 1998). The results from these and previous experi- MMP assay measuring proteolytic activity against Mca-
P-L-G-L-Dpa-A-R indicated elevated levels of MMP ac-ments suggest that RECK serves as a membrane-
anchored regulator for at least three MMP family mem- tivity in the conditioned medium prepared from RECK/
embryonic cells (Figure 3C). Second, in situ zymographybers—MMP-2, MMP-9, and MT1-MMP.
detected a much broader area exhibiting gelatinolytic
activity in sections prepared from RECK/ embryosRECK Is Essential for Mouse Development
(Figure 3D). Third, immunohistochemical analyses forTo understand the physiological functions of this unique
various ECM components revealed that the amount ofMMP regulator, we generated mice lacking a functional
collagen I in the marginal zone of the neural tubes isRECK gene (Figure 2A). Mice heterozygous for the RECK
greatly reduced in RECK/ embryos (Figure 3E) and thatmutation (RECK/) were healthy and fertile, but no ho-
the staining pattern for collagen IV and laminin is largelymozygous pups (RECK/) were born. The ratio of wild-
disrupted around the blood vessels and neural tubes oftype to heterozygous offspring was about 1:2, indicating
the mutant embryos (Figures 3F and 3G), suggestinga recessive lethal phenotype. To determine the time at
partial destruction of the basal lamina. The staining pat-which the effects of RECK deficiency become manifest,
tern of fibronectin was also disrupted; however, thewe examined embryos from heterozygous intercrosses
overall effect on the intensity of fibronectin staining wasat different developmental stages (Figure 2B). No overt
less pronounced (Figure 3H). Finally, electron micros-phenotype was seen in RECK/ embryos at embryonic
copy revealed almost complete loss of collagen fibrilsday 9.5 (E9.5) (data not shown); however, about two-
and an apparently discontinuous basal lamina sur-thirds of the RECK/ embryos died (as judged by lack of
rounding the neural tube in the mutant embryos (com-heartbeat) by E10.5, and no RECK/ embryos survived
pare Figure 3J with Figure 3I). Thus, the integrity ofbeyond E11.5. The lack of RECK gene products in the
collagen fibers and the basal lamina are severely com-homozygous mutant embryos was confirmed by RNA
promised in the absence of RECK. RECK, MMP-2, andblot hybridization (Figure 2C), immunoblot assay (Figure
MT1-MMP are all expressed in this area (Figure 3K),2D), and immunostaining of embryo sections (Figure 2F).
supporting the idea that deregulation of one or both ofSimilar phenotypes and embryonic death of homozy-
these MMPs is responsible for the mutant phenotype.gous mutants were observed in mutants derived from
two independent ES cells lines and in two genetic back-
grounds (129/Sv and C57BL/6J). Expression of RECK in Vascular Smooth
Muscle CellsRECK/ embryos are distinct from their littermates in
their smaller body sizes, a conspicuous reduction in In wild-type E10.5 embryos, the RECK protein is widely
expressed in mesenchymal tissues and is relativelystructural integrity, and frequent abdominal hemorrhage
(Figure 2E). Histological examination revealed severe abundant in the marginal zone of the neural tube and
large blood vessels such as the dorsal aorta (Figure 4A),disarray of mesenchymal tissues and disrupted organo-
genesis in the mutant embryos (Figure 2F and data not areas of greatly impaired distribution of ECM compo-
nents in RECK/ embryos. Around the dorsal aorta, theshown). In particular, vascular endothelial cells do not
form tight and thin tubular structures as seen in the wild- staining pattern for RECK resembles that for -smooth
muscle actin (SMA), suggesting that RECK expressiontype embryos (Figures 2G and 2H). Although vascular
RECK and Angiogenesis
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Figure 3. Effects of RECK Mutation on MMP-2 Processing and ECM Proteins In Vivo
(A) Increased pro-MMP-2 processing in RECK/ cells. Conditioned media from cultured whole embryonic cells were subjected to gelatin
zymography. The genotype of each embryo is shown above.
(B) Suppression of MMP-2 processing by RECK. Conditioned media from RECK/ MEF transfected with the control vector or the vector
containing hRECK cDNA were analyzed by gelatin zymography.
(C) Increased MMP activity in RECK/ cells. Conditioned media from cultured embryonic cells (prepared from a pairs of littermates: #1, #2)
were subjected to gelatin zymography (left panel) and their proteolytic activity against a fluorescent MMP substrate measured (right panel).
The genotype of each embryo is shown above (left panel). MMP activities were compared between a pair of littermates (#1 versus #2) and
presented as a ratio (right panel). Error bar represents SE from three independent measurements. Similar results were obtained with three
pairs of littermates.
(D) In situ zymography of E10.25 embryos. Serial, parasagittal sections of three wild-type and three RECK/ embryos at E10.25 (alive) were
prepared and subjected to in situ zymography. A typical result from each group is shown. Essentially no gelatinolytic activity was detected
with the control film containing an MMP inhibitor, 1,10-phenanthroline (not shown).
(E–H) Effects of the RECK mutation on ECM proteins. The borders between neuroepithelium and mesenchyme in the wild-type (left) or the
RECK/ (right) E10.5 embryo stained with antibodies against collagen I (E), collagen IV (F), laminin (G), or fibronectin (H) are shown.
(I and J) Ultrastructure of the outer surface of the neural tube in a wild-type (I) or a RECK/ E10.5 embryo (J). Collagen fibrils (arrowhead)
were rarely found in RECK/ embryos.
Scale bar: 1 mm in D; 50 m in E–H and K; 0.5 m in I and J.
(K) The border between the marginal zone of the neural tube and the adjacent mesenchymal tissue in the wild-type E10.5 embryo stained
with antibodies against RECK (left), MMP-2 (middle), and MT1-MMP (right).
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is relatively high in vascular smooth muscle cells (Figure
4B). The result of immunogold electron microscopy also
supports this finding (Figure 4C): the flat endothelial
cells facing the lumen bear far fewer signals than the
cells in the second and third rows. The RECK mutation,
however, has little impact on the migration and differen-
tiation of smooth muscle cells, as these cells (stained
with anti-SMA) are found around the blood vessels in
RECK/ embryos (Figure 4D).
Taken altogether, these data suggest that RECK-
dependent maintenance of ECM around blood vessels
is required for vessel maturation and stabilization, but
not for recruitment of the mural cells to the embryonic
vasculature.
Partial Rescue of the RECK Mutant Phenotype
by an MMP-2 Null Mutation
To confirm interaction between RECK and MMP-2
(which is extensively expressed at E10; Reponen et al.,
1992 and Figure 3K) in vivo, we intercrossed MMP-2 null
mice, which, as previously reported (Itoh et al., 1997),
exhibited no developmental abnormality (data not shown),
with RECK/ mice to generate MMP-2/ RECK/ mice.
These mice were found to be healthy and fertile. When
we crossed these MMP-2/ RECK/ mice, no MMP-2/
RECK/ double mutants were born. The ratio of the
MMP-2/ RECK/ to MMP-2/RECK/ offspring was
about 1:2, indicating a recessive lethal phenotype. At
E11.0, about one-third of the MMP-2/ RECK/ animals
were still alive, but none of them survived beyond E11.5
(Figure 5A, striped bars). RECK/ embryos were found
to die about half a day earlier than the double null mice
(Figure 5A, filled bar), indicating that the lethal pheno-
type in the RECK/ mice was partially rescued by the
lack of MMP-2 expression.
It was also noticed that the MMP-2/ RECK/ double
mutant embryos were consistently larger in body size
than the RECK/ embryos at E10.5 (Figure 5B), and that
their tissue integrity was much higher than that of the
RECK/ embryos (Figures 5C–5G, compare the middle
panels with the right panels). Immunohistochemical
analyses indicate that collagen I is detectable in the
marginal zone of the neural tubes (Figure 5C) and that
the patterns of collagen IV and laminin around the blood
vessels and neural tubes are much more organized in
the double mutant embryos than the RECK/ embryos
(Figures 5D and 5E). Moreover, vascular endothelial cells
form tight and thin tubular structures (Figures 5F and
Figure 4. Tissue Distribution of RECK and Other Proteins in E10.5 5G), suggesting improved vascular development in the
Embryos double mutant embryos. These findings suggest that
(A) A wild-type embryo was cut sagittally into two pieces, and whole- MMP-2 is responsible, at least partially, for the reduced
mount immunostaining was performed with (left) or without (middle)
body size, reduced collagen I, and the endothelial disar-anti-RECK antibodies. The anterior half of the embryo cut transver-
ray found in the E10.5 RECK/ embryos.sally at the abdominal level (as shown in the middle figure) was also
stained with anti-RECK antibodies (right).
(B) Large blood vessels (dorsal aorta) in the wild-type embryo Effects of RECK Expression on Tumorigenic
stained with antibodies against RECK, laminin (LN), CD31, or -SMA Growth of HT1080 Cells
(SMA).
To evaluate the pathophysiological implications of(C) Immunogold electron microscopy with anti-RECK antibodies.
RECK expression, HT1080 cells were transfected withThe wall of a large blood vessel in a wild-type embryo is shown.
either a control vector or a vector expressing RECK,(D) Effects of the RECK mutation on vascular smooth muscle cells.
A wild-type (left) or a RECK/ (right) embryo stained with anti-SMA. and after drug selection, pools of transfectants were
Scale bar: 1 mm in A; 50 m in B and D; 1 m in C. inoculated subcutaneously into nude mice. We first
compared the size of the tumors at intervals and found
no significant difference between the two groups (Figure
RECK and Angiogenesis
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Figure 5. Phenotype of the MMP-2/
RECK/ Double Mutant Mice
(A) Proportion of surviving embryos with indi-
cated genotype at indicated stages. n, num-
ber of embryos observed.
(B–G) Sections of the E10.5 embryos with ge-
notypes indicated on the top were stained
with hematoxylin-eosin (B) or antibodies
against collagen I (C), collagen IV (D), laminin
(E), or CD31 (F and G). Scale bar: 1 mm in B;
100 m in C–G.
6A). It was, however, noted that the animals bearing bridization and immunohistochemical staining (Figures
6C and 6D).the RECK-expressing tumors tended to live longer than
those bearing the control tumors (Figure 6B). Continued Histological examination of the tumors at different
stages revealed that tumor angiogenesis was stronglyexpression of RECK in the tumor cells originating from
the RECK transfectants was confirmed by RNA blot hy- affected by RECK expression. Staining with anti-laminin
Cell
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Figure 6. Effects of RECK Expression on HT1080-Derived Tumors in Nude Mice
(A) The size of tumors formed after inoculation of HT1080 cells transfected with a control vector (black line) or a vector expressing the hRECK
gene (blue line). Seven animals were used per group. Note that some animals died during the experiment (see [B]), so the data represent the
tumors in surviving animals. The experiments were repeated twice with similar results.
(B) Survival of the animals inoculated with vector-transfected (black line) or RECK-transfected (blue line) HT1080 cells. The experiments were
repeated twice with similar results. By log-rank test, P  0.046.
(C) Total RNA was extracted from two average-sized tumors arising from vector-transfected cells (lanes 1 and 2) or RECK-transfected cells
(lanes 3 and 4) on day 11 after inoculation and analyzed by RNA blot hybridization using a RECK probe.
(D) Sections were made from the same tumors used in (C) and stained with anti-RECK antibodies.
(E–G) Three animals were sacrificed at three different stages (calculated tumor sizes in cm3: the tumors shown in [E], 0.17 [vector] and 0.21
[RECK]; [F], 0.45 [vector] and 0.67 [RECK]; [G], 6.4 [vector] and 4.6 [RECK]), and the tumors sectioned and then stained with anti-laminin
antibodies.
(H) The number of blood vessels in eight randomly picked fields in a section of a small (S, shown in [A]), medium (M, shown in [B]), or large
(L, shown in [C]) tumor was counted and are presented as average density per mm2. Vessel density is significantly different only between S
and L tumors (P  0.02) arising from vector-transfected cells, but is significantly different between all combinations of tumors arising from
RECK-transfected cells (P  0.01).
(I) A hematoxylin-eosin-stained section of a large RECK-expressing tumor whose host survived over 57 days. Scale bar: 50 m in D; 200 m
in E–G; 500 m in I.
antibodies, which visualize the basal lamina of blood vessels in the control tumors show a narrow, thorny
morphology characteristic of branching vessels (Figuresvessels, clearly demonstrates this effect (Figures 6E–
6G). In the control tumors, the density of the blood ves- 6E–6G, left panels), while the proportion of blood vessels
with wide-opened lumens (unbranched and/or luminallysels stayed almost constant as the tumors grew larger
(Figures 6E–6G, left panels; Figure 6H, left three bars). growing vessels) were significantly higher (2.2–5.5 fold;
P  0.00023) in the RECK-expressing tumors (FiguresIn the RECK-expressing tumors, however, the density
of the blood vessels decreased (Figure 6H). Compart- 6E–6G and data not shown). Interestingly, in very large
RECK-expressing tumors, vascularization was limitedments of cells devoid of blood vessels could be found
even in small RECK-expressing tumors, and such areas to a few very large blood vessels, and only the cells
surrounding these blood vessels survived, with mostexpanded in proportion to the increase in tumor size
(Figures 6E–6G, right panels). Figures 6E–6G also illus- cells inside the vessel-free areas dying (Figure 6I). Thus,
the expression of RECK at high levels in tumor tissuetrate the dramatic increase in vessel cross-sectional
area that occurs in RECK-expressing tumors. Essentially limits angiogenic sprouting and leads to massive tumor
cell death.the same results were obtained by staining with a marker
for endothelial cells (CD31) or for mural cells (-SMA)
(data not shown). Discussion
This difference could be explained by assuming that
in the RECK-expressing tumors, angiogenic sprouting Our studies have demonstrated that RECK can inhibit
three MMP family members, MMP-2, MMP-9, and MT1-is suppressed, and instead, luminal growth occurred.
Consistent with this hypothesis, the majority of the blood MMP. MMP-2 and MMP-9 efficiently digest denatured
RECK and Angiogenesis
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Figure 7. Effects of RECK on MMPs and An-
giogenesis
(A) Summary of the effects of RECK on MMPs.
RECK is associated with the membrane
through GPI-anchoring. RECK apparently in-
hibits the release of pro-MMP-9 from the cells
(Takahashi et al., 1998), and also inhibits the
enzyme activity of MT1-MMP and MMP-2, re-
sulting in reduced production of active
MMP-2 (this study).
(B) A model to explain our findings in vivo.
See text for details.
collagen (Nagase and Woessner, 1999); MT1-MMP not gous for the mutant collagen 1(I) gene also die in utero
by the rupture of major blood vessels (Lohler et al.,only participates in the processing of pro-MMP-2 but
also digests various ECM components in vitro, including 1984).
A group of smaller (20–30 kDa) MMP inhibitors,collagen I (Pei and Weiss, 1996; Ohuchi et al., 1997).
Hence, these MMPs could act alone or in concert to TIMP-1 to TIMP-4, have been identified and character-
ized (Brew et al., 2000). A critical difference betweendigest collagen fibers, and RECK would inhibit this pro-
cess. Consistent with this model, collagen fibers around RECK and TIMPs lies in their localization: RECK is mem-
brane-anchored, while TIMPs are secreted. Membranethe neural tube, whose peripheral region expresses
RECK, MMP-2, and MT1-MMP (Figure 3K), are dramati- anchoring allows RECK to be concentrated on the
plasma membrane (unpublished data) and to effectivelycally reduced in RECK-deficient mouse embryos (Fig-
ures 3E and 3J). Thus, a simple model to explain the regulate local proteolytic events at the cell surface,
where proteolytic processing of MMPs occurs (Werb,mutant phenotype would be that RECK protects colla-
gen fibrils from degradation catalyzed by these MMPs 1997). Additionally, the lack of RECK is embryonic lethal
in mice, while the lack of TIMP-1 or TIMP-2 has littlein the wild-type animal. Our findings that the loss of
MMP-2 expression could partially rescue the phenotype effect on development (Nothnick et al., 1997; Wang et
al., 2000; Caterina et al., 2000), suggesting that RECKof RECK/ mice and that collagen I could be detected in
the MMP-2/RECK/ double mutant embryos at E10.5 shares little functional redundancy with the TIMPs, at
least during this stage (E10.5) of mouse development.suggest that MMP-2 is one of the multiple molecules
affected by RECK in vivo and that increased MMP-2 Ras is known to affect cell-ECM interaction in several
ways: activated Ras downregulates several ECM pro-activity is largely responsible for the decreased collagen
I seen in the RECK/ mice. Our preliminary results indi- teins, such as fibronectin and collagen I, as well as ECM-
receptors (integrins) (Fagan et al., 1981; Howard et al.,cate, however, that the loss of MT1-MMP expression
fails to rescue the phenotype of RECK/ mice (data not 1978; Plantefaber and Hynes, 1989), while it upregulates
several MMPs (Garbisa et al., 1987; Thant et al., 1997).shown). Thus, interaction between MT1-MMP and RECK
in vivo remains to be established. Nevertheless, the idea These changes contribute in concert to the manifesta-
tion of the transformed phenotype, especially reducedthat reduced collagen is causal to the vascular defects
is consistent with the earlier finding that mice homozy- adhesion to the substrate. Our findings add another
Cell
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essential component to this picture: RAS-mediated sion should be evaluated as possible therapeutic or pre-
downregulation of RECK, which allows the MMPs to ventive agents for cancer.
elicit their full activity.
Experimental ProceduresFigure 7 illustrates an interpretation of our findings in
vivo. In the RECK/ E10.5 mouse embryos, RECK is not
Cell Cultureexpressed in blood vessels or in the surrounding tissue;
HT1080 (human fibrosarcoma) cells were maintained in growth me-
under these conditions, vasculogenesis occurs, but dium (GM) as described previously (Kitayama et al., 1989). The cells
maturation of the vasculature is compromised (Figure (3  104/35 mm dish) were transfected with the mammalian expres-
sion vector pCXN2 (Niwa et al., 1991) or pCXN2 containing human7B, left cartoon). In the wild-type embryo, RECK is ex-
RECK (hRECK) cDNA (2 g) by the standard calcium phosphatepressed in blood vessel cells, especially in mural cells,
method, and after selection for 10 days with GM containing 1 mg/while its expression is low in the surrounding tissue. The
ml G418, stable transfectant colonies were pooled and passagedsituation is likely to be similar in the control HT1080
several times (1:20, every 3–4 days) in the selection medium before
tumors proliferating in nude mice: due to the activated being used for experiments. Methods for preparing conditioned me-
N-ras oncogene expressed by HT1080 cells (Brown et dia and gelatin zymography have been described elsewhere (Taka-
al., 1984), RECK is downregulated in the tumor tissue hashi et al., 1998).
(see Figure 1), while the blood vessel cells are of mouse
Determination of MMP Activityorigin and probably express RECK. Under these condi-
The same fluorescent peptide, (7-methoxycoumarin-4-yl)Acetyl-Pro-tions, the integrity of the blood vessels is not impaired,
Leu-Gly-Leu-(3-[2,4-dinitrophenyl]-L-2,3-diaminopropionly)-Ala-nor is angiogenic sprouting inhibited (Figure 7B, middle
Arg-NH2 (Mca-P-L-G-L-Dpa-A-R) (Peptide Institute, Osaka, Japan)cartoon). In the RECK-expressing HT1080 tumors, how- (Knight et al., 1992), was used as the substrate in the following three
ever, the vasculature is defective. In these tumors, the types of assays:
defect is not due to the inability of the vasculature to (1) MT1-MMP
An aliquot of MT1-F protein (soluble FLAG-tagged MT1-MMP) ex-mature, but rather to inhibition of angiogenic sprouting
pressed in E. coli and immobilized on anti-FLAG M2 beads (IHI) as(Figure 7B, right cartoon). A simple model can explain
described previously (Kinoshita et al., 1998) was incubated in 50 lthese findings: in the absence of RECK expression, ex-
assay buffer (0.1 M Tris-HCl [pH 7.5], 0.1 M NaCl, 10 mM CaCl2, andcess MMP activity results in excessive degradation of 0.05% Brij-35) containing 10 M substrate with or without BSA (4
the ECM, causing reduced structural integrity of the pmol), hRECKC (2 or 4 pmol), or TIMP-2 (0.25 pmol) at 25	C for
blood vessels (and perhaps of the surrounding tissue). 20 min. The reaction was terminated by adding 80l of 0.1 M sodium
acetate (pH 4.0), and the hydrolysis of the substrate was measuredThis in turn retards maturation of the early vascular net-
with a spectrofluorimeter (Shimazu RF-1500; 
ex  328 nm, 
em work. In the presence of high RECK expression, MMP
393 nm) at 25	C.activity is reduced to the point where ECM remodeling
(2) MMP-2is compromised and the ability of preexisting blood ves-
Pro-MMP-2 (1 g, Boehringer Mannheim) was activated in 5 l of
sels to send out capillary sprouts and produce new 0.75 mM APMA, 20 mM Tris-HCl (pH 7.5), 50 mM NaCl, and 10 mM
vessels is inhibited. Thus, the magnitude and spatial CaCl2 at 37	C for 5 min. At this time point, about 80% of the maximum
pattern of RECK and MMP activity are crucial for normal level of activation was achieved, and further incubation gave rise
to smaller degradation products (data not shown). Immediately afterangiogenesis: high RECK and low MMP activity would
activation, the enzyme (0.25 g) was mixed with different amountsbe predominant in areas where angiogenesis is sup-
of substrate in the presence or absence of hRECKC (3.5 pmol) inpressed, e.g., around the major arteries, and lower RECK
50 l assay buffer and incubated at 25	C for 10 min. The Ki valueand higher MMP activity would be predominant in areas was calculated using the equation 1/V  1/Vmax  Km (1  [I]/Ki)/
where angiogenesis normally occurs. Vmax [S].
However, it is unclear exactly why vascular develop- (3) Conditioned Media
MMP activity in an aliquot (the amount corresponding to 3  104ment stops when RECK is absent. While our biochemical
cells) of conditioned medium was measured in a 50 l reactionand histological data suggest that accelerated degrada-
mixture as described in (1) without addition of any other proteins.tion of ECM components, such as collagen I, is likely to
be the primary consequence of RECK-deficiency, it is
RNA Blot Hybridization and Immunoblot Assaypossible that RECK also regulates the amount or fate
Total RNA was extracted and analyzed by RNA blot hybridization
of certain extracellular signaling molecules (e.g. trans- using 32P-labeled mouse or human RECK cDNA (Takahashi et al.,
forming growth factor-, vascular endothelial growth 1998), human MT1-MMP cDNA (Sato et al., 1994), human TIMP-2
factor, thrombospondin, etc.), which in turn regulate col- cDNA, or human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA. To extract proteins, cultured cells or mouse em-lagen production or other aspects of angiogenesis (Vu
bryos were homogenized in 50 mM Tris.HCl (pH 6.8), 1% SDS, 1and Werb, 2000). Further studies using the experimental
mM EDTA containing 1 mM PMSF, 16 mM soybean trypsin inhibitor,systems described here may help in identifying an addi-
and 3.5 mM aprotinin. The lysates were cleared by centrifugation,tional molecular target(s) for RECK in vivo.
and their protein concentration determined. The sample (70 g pro-
Good correlation has been found between the abun- tein) was separated by SDS-PAGE (10% acrylamide), followed by
dance of RECK expression in hepatoma samples and immunoblot detection using monoclonal antibodies against RECK
the survival of the patients (Furumoto et al., 2001). This (5B11D12), MT1-MMP (114-6G6), or MMP-2 (42-5D11). For visualiza-
tion, the Enhanced Chemiluminescence kit (Amersham) was usedfinding is reminiscent of the survival curve of nude mice
with HRP-conjugated anti-mouse IgG-F(ab)2 monoclonal antibodybearing RECK-expressing HT1080 tumors (Figure 6B).
(Wako).Thus, RECK expression can be a good prognostic indi-
cator for cancer patients. Moreover, since overexpres-
Generation of Mutant Mice
sion of RECK in tumors was found to affect tumor angio- Fragments of the mouse RECK gene were cloned from the 
FixII-
genesis as well as invasion and metastasis, application 129/Sv genomic library (Stratagene) (Sasahara et al., 1999). The 4.0
of the RECK gene, the RECK protein, its chemical mi- kilobase (kb) SpeI-SmaI fragment upstream of the first exon and
the 2.5 kb HindIII fragment downstream of the first exon were in-metic, or drugs activating endogenous RECK expres-
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serted into the XbaI and HindIII sites, respectively, of the PGK-neo- by gelatin zymography. MEF were established by continued passag-
ing (more than 35 times) of these cultures.DTA vector (Yagi et al., 1990). This targeting vector was linearized
with NotI and introduced by electroporation into E14 ES cells. G418-
resistant clones carrying the mutant allele were selected and in- Formation and Analyses of Tumors in Nude Mice
jected into C57BL/6J blastocysts (Gomi et al., 1995). Chimeric HT1080 cells transfected with empty pCXN2 or pCXN2 containing
males, identified by coat color, were bred to C57BL/6J and 129/Sv hRECK cDNA were trypsinized, suspended at 5  107/ml in PBS
females. containing antibiotics, and inoculated subcutaneously into the back
Generation, genotyping, and characterization of MMP-2-deficient of 4 week old female Balb/c nu/nu mice (0.2 ml per site/animal; n 
mice have been described (Itoh et al., 1997). The RECK/ mice 10). Sizes (length, width, and height) of the tumors were measured
were first backcrossed into the C57BL/6 strain five generation and weekly, and three animals were sacrificed at appropriate time points
then intercrossed with the MMP-2/ mice to generate MMP-2/ for histological examination. Survival of the remaining 7 animals was
RECK/ mice. These double heterozygotes were crossed to obtain monitored 2–3 times a week. The experiments using mice were
MMP-2/ RECK/ mice which were then crossed each other to carried out following institutional guidelines. Measurements on mi-
obtain MMP2/ RECK/ embryos. croscopic images were carried out using the software NIH Image.
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